Endogenous nonapeptide hormone

Plain-language summaryIntrigue 60 / 100

Vasopressin (antidiuretic hormone) and the synthetic analog DDAVP (desmopressin) regulate water retention by the kidneys. Used clinically for diabetes insipidus and bedwetting. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Well-understood approved neuropeptide with solid clinical data but limited frontier research appeal

Look, vasopressin is one of those compounds where the clinical story is genuinely impressive and the research-frontier story is… not. It’s been known as antidiuretic hormone since the 1950s, the V1a/V1b/V2 receptor pharmacology is textbook-level established, and DDAVP has been FDA-approved for central diabetes insipidus since the late 1970s. The approved indications work, the mechanism is understood, and the hemostatic use in hemophilia A and von Willebrand disease type 1 represents real clinical value. None of that translates into a compelling research target for 2025.

The mechanism isnt bad on paper. V1b agonism in pituitary corticotrophs puts AVP squarely in the HPA axis conversation alongside CRH, and theres genuine academic interest in how the AVP/CRH synergy regulates ACTH release under stress. The social neuroscience angle, made famous by prairie vole studies on V1aR and pair bonding, spawned a decade of intranasal paradigms looking at trust, social memory, and aggression. We think that literature is interesting but also somewhat exhausted. The human signal for vasopressin’s social and cognitive effects has been inconsistent, and the intranasal delivery route introduces confounds that have complicated interpretation for years.

What we do like: DDAVP’s selectivity for V2 over V1 receptors makes it a reasonably clean probe for aquaporin-2 trafficking and collecting duct water transport physiology. If your lab is doing renal tubular biology or studying aquaporin regulation, DDAVP earns its place on the shelf. For V1b work on stress axis biology, native AVP is more appropriate than the synthetic analog. Those are real and defensible bench applications, just not frontier ones.

The cognitive enhancement use case, historically delivered at 1 to 2 IU intranasally, has a thin and unreplicated evidence base. The early Weingartner studies from the 1980s were never robustly confirmed. This isnt a developing story; it’s a closed one. The signal didnt survive scrutiny, and the more tractable approaches to neuropeptide-based cognition research have moved elsewhere.

Honestly, vasopressin scores where it scores because the compound is genuinely useful pharmacology in its approved lane and has bench probe value in specific subfields, but there’s no frontier angle that would make a serious investigator prioritize it over newer targets. High evidence quality and translational confidence for what it does; low novelty and differentiation for what it doesnt. That’s the tension that lands it here.

Novelty: 22
Mechanism promise: 33
In-category differentiation: 35
Evidence quality: 75
Translational signal: 70
Research bench value: 50

Rationale Vasopressin is a decades-old endogenous hormone with FDA-approved indications and a thoroughly mapped receptor pharmacology; its evidence quality and translational signal are high for approved uses, but novelty is low and the cognitive-enhancement research angle that made it culturally interesting in nootropic circles has largely failed to produce meaningful human signal, dragging differentiation and mechanism promise toward the middle of the scale.

Endogenous nonapeptide hormone

An endogenous nonapeptide hormone for water retention and vasoconstriction; the synthetic analog desmopressin (DDAVP) is FDA-approved for diabetes insipidus.

Abstract

Vasopressin (arginine vasopressin, AVP, antidiuretic hormone; CAS 113-79-1; molecular weight 1084.23) is an endogenous nonapeptide synthesized in the paraventricular and supraoptic nuclei. The synthetic analog desmopressin (DDAVP; deamino-D-arginine vasopressin) is FDA-approved for diabetes insipidus, primary nocturnal enuresis, hemophilia A, and von Willebrand disease type 1. Mechanism includes V1a (vascular smooth muscle), V1b (pituitary corticotrophs), and V2 (renal collecting duct) receptor agonism. Cognitive enhancement applications historically used intranasal vasopressin (1 to 2 IU intranasally) but the evidence base is weak and current clinical use is largely limited to the approved water-balance and hemostatic indications.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-136Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Endogenous nonapeptide hormone

Vasopressin (DDAVP)

Abstract

Read the full monograph